MedTrace Logo

Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors

NCT04602702 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-04-05

No results posted yet for this study

Summary

The Investigators will use novel PDX (patient-derived xenograft) technology to form xenografts using material from metastatic solid tumor patients. Xenografts will be treated with a panel of drugs to determine which agent(s) yield the greatest anti-tumor effect on the xenograft.

Conditions

  • Kidney Neoplasm
  • Carcinoma, Renal Cell
  • Metastatic Solid Tumor

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Georg Bjarnason, MD · Sunnybrook Hospital/Odette Cancer Centre

  • Elyse Watkins, BSc, PGDip · Sunnybrook Hospital/Odette Cancer Centre

  • Nir Lipsman, MD · Sunnybrook Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04602702 on ClinicalTrials.gov